Gemini Therapeutics, Inc. (GMTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
GMTX Stock Price Chart Interactive Chart >
GMTX Price/Volume Stats
|Current price||$1.26||52-week high||$12.95|
|Prev. close||$1.22||52-week low||$1.16|
|Day high||$1.29||Avg. volume||259,891|
|50-day MA||$1.46||Dividend yield||N/A|
|200-day MA||$2.61||Market Cap||54.47M|
Gemini Therapeutics, Inc. (GMTX) Company Bio
Gemini Therapeutics, Inc. operates as a precision medicine company. The Company focuses on dry macular degeneration which is a disease comprised of numerous genetic variants. Gemini Therapeutics serves customers worldwide.
Most Popular Stories View All
GMTX Latest News Stream
|Loading, please wait...|
GMTX Latest Social Stream
View Full GMTX Social Stream
Latest GMTX News From Around the Web
Below are the latest news stories about Gemini Therapeutics Inc that investors may wish to consider to help them evaluate GMTX as an investment opportunity.
CAMBRIDGE, Mass., January 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program.
Gemini Therapeutics (NASDAQ:GMTX) had its price target reduced by SVB Leerink from $25.00 to $15.00 in a report released on Monday, PriceTargets.com reports. SVB Leerink currently has an outperform rating on the stock. A number of other research analysts also recently commented on the stock. The Goldman Sachs Group cut their target price on shares 
Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX) have been given an average recommendation of Buy by the six brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages 
Gemini Therapeutics (NASDAQ:GMTX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, Gemini Therapeutics Inc. is a clinical stage precision medicine company. It engages in developing novel therapeutic compounds to treat genetically defined age-related macular degeneration. The companys lead  The post Gemini Therapeutics (NASDAQ:GMTX) Rating Lowered to Hold at Zacks Investment Research appeared first on ETF Daily News .
H.C. Wainwright analyst Matthew Caufield initiated coverage with a Buy rating on Gemini Therapeutics (GMTX – Research Report) today and set a price target of $20.00. The company's shares closed last Tuesday at $2.43, close to its 52-week low of $2.28. According to TipRanks.com, Caufield is ranked #4051 out of 7739 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gemini Therapeutics with a $22.50 average price target. See the top stocks recommended by analysts >> The company has a one-year high of $19.09 and a one-year low of $2.28. Currently, Gemini Therapeutics has an average volume of 120.5K.
GMTX Price Returns